Revolution Medicines’ $273.7 Million Initial Public Offering


Latham & Watkins LLP acted as special counsel to Revolution Medicines, Inc., while Davis Polk advised the underwriters on the deal.

Revolution Medicines, Inc. completed its initial public offering of 16,100,000 shares of common stock at $17.00 per share (which includes the exercise in full by the underwriters of their option to purchase up to 2,100,000 additional shares), for total gross proceeds of $273.7 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “RVMD.”

J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as joint book-running managers for the offering.

Based in Redwood City, California, Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, high-value frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways.

The Davis Polk corporate team included partner Alan F. Denenberg (Picture) and associates Beth LeBow and Daniel Reichert. The intellectual property and technology team included partner David R. Bauer and associate Jay Frankel. The tax team included partner Rachel D. Kleinberg and associate Adam R. Brownstone. Counsel Marcie A. Goldstein provided FINRA advice. Associate Sijia Cai provided 1940 Act advice.

Involved fees earner: David Bauer – Davis Polk & Wardwell; Adam Brownstone – Davis Polk & Wardwell; Sijia Cai – Davis Polk & Wardwell; Alan Denenberg – Davis Polk & Wardwell; Jay Frankel – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Beth LeBow – Davis Polk & Wardwell; Daniel Reichert – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Cowen and Company; Guggenheim Securities; J.P. Morgan Securities LLC; SVB Leerink LLC;